LIVN · LivaNova PLC
$80.77
-0.66 (-0.81%)
At close · Jul 30
Market Cap
$4.47B
Shares
54.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.39B
+10.7%
FY2025
Net Income
-$242.47M
-483.5%
FY2025
Gross Margin
67.71%
-0.4pp
FY2025
Operating Margin
14.36%
+4.1pp
FY2025
Diluted EPS
-$4.45
-483.6%
FY2025
Operating Cash Flow
$254.34M
+39%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.43B | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B | $934.24M | $1.08B | $1.11B | $1.01B | $964.86M | $291.56M | |
| $466.09M | $448.18M | $399.95M | $397.73M | $314.58M | $329.37M | $339.48M | $360.37M | $361.32M | $353.19M | $367.85M | $27.31M | |
| $967.37M | $939.87M | $853.48M | $755.82M | $707.23M | $705.99M | $594.76M | $723.81M | — | $651.62M | $559.51M | $264.25M | |
| — | 67.71% | 68.09% | 65.52% | 69.21% | 68.19% | 63.66% | 66.76% | — | 64.37% | 57.99% | 90.63% | |
| $206.58M | $185.76M | $182.51M | $193.82M | $155.81M | $183.41M | $152.9M | $146.85M | $145.95M | $109.52M | $82.08M | $43.28M | |
| $563.24M | $548.81M | $508.88M | $502.7M | $469.24M | $471.9M | $446.56M | $528.47M | $464.97M | $380.1M | $355.16M | $123.62M | |
| — | $17.7M | $17.21M | $25.47M | — | — | $0 | $0 | $37.19M | $33.14M | $31.04M | $1.5M | |
| — | — | — | — | — | — | — | — | — | — | $85.36M | $6.81M | |
| — | -$177K | $13.36M | $956K | $6.61M | $9.71M | $0 | $0 | $15.92M | $17.06M | $37.38M | $0 | |
| $655.91M | — | — | — | — | — | — | — | — | $555.95M | $528.06M | $175.6M | |
| $192.24M | $199.39M | $129.05M | -$68.5M | -$76.75M | -$784K | -$273.9M | -$171.55M | -$248.07M | $96.49M | $33.45M | $88.65M | |
| — | 14.36% | 10.3% | -5.94% | -7.51% | -0.08% | -29.32% | -15.82% | -22.41% | 9.53% | 3.47% | 30.41% | |
| — | — | — | — | — | — | — | — | — | — | $118.81M | $95.46M | |
| $42.29M | $49.29M | $63.07M | $58.85M | $48.25M | $50.15M | $40.84M | $15.09M | $9.83M | $7.8M | $10.62M | $21K | |
| — | $18.98M | $30.08M | $22.01M | $4.7M | $435K | $131K | $803K | $847K | $1.32M | $1.7M | $184K | |
| -$19.79M | -$2.68M | $47.81M | $46.13M | $691K | — | — | — | — | — | — | — | |
| -$882K | -$51K | -$18K | -$104K | -$53K | -$148K | -$264K | $0 | -$644K | -$16.72M | -$18.68M | $0 | |
| -$1.01M | -$3.62M | $7.14M | $0 | $0 | $4.64M | $0 | $0 | — | — | — | — | |
| $122.35M | -$220.78M | $88.31M | -$81.23M | -$75.14M | -$124.47M | -$348.02M | -$188.38M | -$247.45M | $121.14M | $25.67M | $89.29M | |
| $14.32M | $21.64M | $25.06M | -$98.88M | $11.05M | $11.2M | -$960K | -$30.37M | -$69.63M | $49.95M | $5.11M | $31.45M | |
| $107.15M | -$242.47M | $63.23M | $17.55M | -$86.25M | -$135.82M | -$348.82M | -$157.64M | -$189.4M | -$25.09M | -$62.79M | $57.85M | |
| — | -17.47% | 5.04% | 1.52% | -8.44% | -13.12% | -37.34% | -14.54% | -17.11% | -2.48% | -6.51% | 19.84% | |
| $146.47M | -$154.97M | $10.95M | $37.78M | -$127.19M | -$170.8M | -$301.62M | -$152.56M | -$259.19M | $88.71M | -$77.05M | $53.99M | |
| USD/shares | — | -$4.45 | $1.17 | $0.33 | -$1.61 | -$2.68 | -$7.18 | -$3.21 | -$3.91 | -$0.52 | -$1.29 | $2.19 |
| USD/shares | — | -$4.45 | $1.16 | $0.32 | -$1.61 | -$2.68 | -$7.18 | -$3.26 | -$3.91 | -$0.52 | -$1.28 | $2.17 |
| shares | — | 54.55M | 54.24M | 53.94M | 53.47M | 50.63M | 48.59M | 48.35M | 48.5M | 48.16M | 48.86M | 26.39M |
| shares | — | 54.55M | 54.57M | 54.21M | 53.47M | 50.63M | 48.59M | 48.35M | 48.5M | 48.5M | 49.01M | 26.63M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2020: $159.5M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.94×
Peer median 2.46×
EV/EBIT
21.96×
Peer median 22.76×
P/E (TTM)
41.55×
Peer median 32.00×
Peer medians compare against the 46 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary Segment | $785,385,000 | $683,512,000 | $604,112,000 | $514,198,000 | $482,979,000 | $446,732,000 | $504,716,000 | — |
| Neuromodulation Segment | $592,812,000 | $554,223,000 | $519,710,000 | $476,993,000 | $456,172,000 | $354,444,000 | $424,547,000 | $422,990,000 |
| Advanced Circulatory Support Segment | — | — | $40,322,000 | $39,301,000 | $55,459,000 | $42,321,000 | $31,923,000 | — |
| Cardiovascular Segment | — | — | — | — | — | $577,083,000 | $656,646,000 | $681,825,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $739,573,000 | $695,083,000 | $635,044,000 | $571,558,000 | $571,299,000 | $468,634,000 | $546,484,000 | $553,411,000 |
| Locations Excluding the United States and Europe | $379,304,000 | $338,322,000 | $303,709,000 | $271,445,000 | $262,542,000 | $272,240,000 | $314,503,000 | $324,549,000 |
| Europe | $269,176,000 | $220,032,000 | $214,792,000 | $178,802,000 | $201,524,000 | $193,367,000 | $223,183,000 | $229,001,000 |
| United Kingdom | $55,900,000 | $48,900,000 | $41,500,000 | $32,300,000 | $35,800,000 | $29,700,000 | $37,700,000 | $34,800,000 |
| Rest of World | — | — | — | — | — | — | $314,503,000 | $324,549,000 |
By Product & Service (USD)
| Component | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Cardiopulmonary | $446,732,000 | $504,716,000 | $536,408,000 | $497,324,000 |
| Heart Valves | $88,030,000 | $120,007,000 | $125,956,000 | $138,193,000 |
| Advanced Circulatory Support | $42,321,000 | $31,923,000 | $19,461,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Neuromodulation Segment | $215,474,000 | $195,309,000 | $153,384,000 | $172,775,000 | $169,499,000 |
| Cardiopulmonary Segment | $108,301,000 | $76,848,000 | $26,407,000 | $11,247,000 | -$6,429,000 |
| Advanced Circulatory Support Segment | — | — | -$117,418,000 | -$142,590,000 | $2,195,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cardiopulmonary Segment | 13.8% | 11.2% | 4.4% | 2.2% | -1.3% |
| Neuromodulation Segment | 36.3% | 35.2% | 29.5% | 36.2% | 37.2% |
| Advanced Circulatory Support Segment | — | — | -291.2% | -362.8% | 4% |
Key facts
CIK
1639691
CUSIP
G5509L101
13F (30d)
76 filings
76 filers
Visit website
Investor relations